New Board members include Susan Podlogar, M.B.A., Jeffrey Feike, M.P.H., and Lindee Goh, Ph.D. A full list of the Board of Directors can be found on Tevogen’s website
Tevogen Bio CEO Ryan Saadi, M.D., M.P.H., and Curtis Patton, Ph.D., Professor Emeritus at Yale University, will continue to serve on the Board of Directors alongside the new members
WARREN, N.J., August 17, 2022--(BUSINESS WIRE)--Tevogen Bio, a late-stage clinical biotechnology company specializing in the development of cell and gene therapies in oncology, neurology, and virology, is pleased to announce the appointment of three new members to its Board of Directors. The new members include Susan Podlogar, M.B.A., Jeffrey Feike, M.P.H., and Lindee Goh, Ph.D. These nationally prominent healthcare leaders join Tevogen’s Board, effective immediately, alongside existing board members, Curtis Patton, Ph.D., and CEO Ryan Saadi, M.D., M.P.H.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220817005492/en/
Tevogen Bio's new Board of Directors members include Jeffrey Feike, M.P.H., Susan Podlogar, M.B.A., and Lindee Goh, Ph.D. (Photo: Business Wire)
The Board of Directors provides direction and guidance to Tevogen’s Executive Committee on strategy, policy, governance, and the achievement of milestones in accordance with company’s mission. The Board is tasked with further strengthening Tevogen’s organizational readiness as the company pursues its bold growth strategy.
"Susan, Jeffery, and Lindee are wholly committed to our corporate culture of creativity, optimism, respect, and equality and our aspiration to be the very first biopharma company to achieve commercial success while ensuring patient affordability," said Tevogen CEO Ryan Saadi, M.D., M.P.H. "These new members bring decades of experience across critical aspects of the healthcare industry and will be integral to expediting the company’s current and future research endeavors and strategic business decisions."
Susan Podlogar is MetLife’s Chief Human Resources Officer. Susan champions a prepared workforce and organization for the future. She is focused on upskilling employees globally and has gained support for the Workforce of the Future Development Fund and accelerated an internal talent marketplace. She also has a proven commitment to realizing a purpose-driven, inclusive culture where employees are energized to make a difference. Internal programs and external commitments, such as the Catalyst CEO Champions for Change pledge, the UN Women Global Innovation Coalition for Change, and the One Mind at Work pledge, are key drivers of this work. Podlogar also serves on MetLife Foundation’s Board of Directors. She also is called upon to provide thought leadership on innovative HR practices to various governmental and educational institutions. Previously, Podlogar served as the Global Vice President of Human Resources for Johnson & Johnson (J&J). Podlogar earned her MBA from the University of South Florida, with concentrations in Finance and Management, and a bachelor’s degree from the University of Wisconsin-Parkside, with a double major in Labor and Industrial Relations and Business Administration.
Jeffrey Feike is a public health servant-leader with 30+ years of experience as CEO of multiple hospitals. In his distinguished career he has overseen the development of hospitals, outpatient clinics, and EMS systems coupled with a wide array of medical programs including Cancer Centers, Stroke Centers, and Trauma Centers. His hospitals have received national recognition from both the Joint Commission and the VHA for outstanding clinical excellence. He is past Chairman of the Nevada Hospital Association, and a 30-year member of the American College of Healthcare Executives. Feike holds an MPH from Tulane University graduating summa cum laude and has been inducted into the national public health honor society, Delta Omega." He also serves as Tevogen’s Chief Patient Officer and is a member of the Innovation and Public Health Advisory Council (IPHAC).
Lindee Goh leads Tapestry Networks’ healthcare practice, working with public and private sector leaders to develop effective strategies to improve clinical outcomes while fostering sustainable healthcare innovation. In doing this, she co-led several working groups, covering topics including the design and implementation of the parallel scientific advice process, approach to regulation and reimbursement in Europe, recommendations to address innovation, diagnostics, & infrastructure challenges of Alzheimer’s disease, molecular diagnostic quality assurance in precision medicine, healthcare financing and payment models in oncology and rare diseases, and multicancer early detection consortium. Before Tapestry Networks, Goh led teams at the Boston Consulting Group, working in biopharma, payer, and provider spaces. Goh holds a doctorate in biology and works as a Howard Hughes Medical Institute Fellow at the Center for Cancer Research at the Massachusetts Institute of Technology (MIT). She completed post-graduate work at MIT as a Leukemia and Lymphoma Fellow in neuroscience. She received her BS Honors in Biology from Caltech. Goh also serves as a member of Tevogen’s IPHAC.
About Tevogen’s Next Generation Precision T Cell Platform
Tevogen’s next generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells, while allowing healthy cells to remain intact. Multiple targets are selected in advance with the goal of overcoming mutational capacity of cancer cells and viruses.
Tevogen is investigating its technology’s potential to overcome the primary barriers to the broad application of personalized T cell therapies: potency, purity, production-at-scale, and patient-pairing, without the limitations of current approaches. Tevogen’s goal is to open the vast and unprecedented potential of developing personalized immunotherapies for large patient populations impacted by common cancers and viral infections.
Tevogen recently announced that it completed enrollment in the Proof-of-Concept clinical trial of its lead product, TVGN-489, for ambulatory, acute-risk COVID-19 patients, with no dose-limiting toxicities or significant treatment-related adverse events observed for any patient at any dose level.
TVGN-489 is a genetically unmodified, off-the-shelf, allogeneic cytotoxic CD8+ T lymphocyte (CTL) product with activity against multiple, precise targets across the SARS-CoV-2 genome.
Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises. Tevogen’s leadership believes that accessible personalized immunotherapies are the next frontier of medicine, and that disruptive business models are required to sustain medical innovation in the post-pandemic world.
This press release contains certain forward-looking statements relating to Tevogen Bio™ Inc (the "Company") and its business. These statements are based on management’s current expectations and beliefs as of the date of this release and are subject to several factors which involve known and unknown risks, delays, uncertainties, and other factors not under the Company’s control that may cause actual results, performance or achievements to be materially different from the results, performance or other expectations implied by these forward-looking statements. Forward-looking statements can sometimes be identified by terminology such as "may," "will," "should," "intend," "expect," "believe," "potential," and "possible," or their negatives or comparable terminology, as well as other words and expressions referencing future events, conditions, or circumstances. In any forward-looking statement in which the Company expresses an expectation or belief as to future results, there can be no assurance that the statement or expectation or belief will be achieved. Various factors may cause differences between the Company’s expectations and actual results, including, among others: the Company’s limited operating history; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, and approval and commercial development; risks associated with intellectual property protection; and risks related to matters that could affect the Company’s future financial results, including the commercial potential, sales, and pricing of the Company’s products. Except as required by law, the Company undertakes no obligation to update the forward-looking statements or any of the information in this release, or provide additional information, and expressly disclaims any and all liability and makes no representations or warranties in connection herewith or with respect to any omissions therefrom.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220817005492/en/
Media: Katelyn Joyce Corporate Communications Lead T: 1 877 TEVOGEN, Ext 709 Katelyn.joyce@tevogen.com
Mayar Capital, an asset management firm, published its second-quarter 2022 investor letter – a copy of which can be downloaded here. For the three months ending March 31, 2021, Mayar Fund (Class A) was down 6.6% net of all expenses and fees, while the MSCI World Index declined by 5.2% in the same period. Since […]
In the world of stock legends, George Soros stands out. While his political activities have been a lightning rod for controversy, no one can doubt his financial acumen. After all, he’s the ‘man who broke the Bank of England,’ and made a billion dollars in one day when he shorted the Pound Sterling back in 1992. His hedge fund, Soros Fund Management, showed three decades of sustained gains, averaging 30% annual returns through the year 2000. During this time, and today in the management of his pe
Yahoo Finance Live co-anchor Seana Smith looks at several trending stocks moving in after-hours trading.
Shares of StoneCo (NASDAQ: STNE), a cloud-based technology platform, plummeted Friday morning after the company reported its second-quarter results, which disappointed investors, and announced yet another shift to its management team. The company reported non-GAAP (adjusted) earnings of 0.25 Brazilian reals (equivalent to $0.05), which was an increase from a loss of 0.48 reals in the year-ago quarter, but was below Wall Street's consensus estimate of about 0.57 reals, or $0.11 per share. StoneCo's revenue in the quarter was 2.3 billion reals (about $442 million), 5% higher than the company's guidance, and up 275% from the year-ago quarter.
A 20-year-old USC student has made a $110 million profit from trading meme stock favorite Bed Bath & Beyond, following a frenzy in Wednesday’s trading session.
Back up the EV on shares of General Motors, says this one analyst.
It's no wonder Altria's (NYSE: MO) stock has lost more than a fifth of its value in just a couple of months. Marketing partner Philip Morris International (NYSE: PM) is getting cold feet on working with Altria to sell its IQOS heated tobacco device while also just acquiring the leading competitor to Altria's own smokeless tobacco products. At the same time, the federal government all but obliterated Altria's $13 billion investment in Juul Labs, the one-time electronic-cigarette leader.
(Bloomberg) -- Warren Buffett’s Berkshire Hathaway Inc. won approval from US regulators to buy as much as 50% of Occidental Petroleum Corp. after spending months snapping up its shares. Occidental’s stock had its biggest gain in five months.Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesStocks Slide as Short-Sellers Cash In on Fedspeak: Markets WrapM
(Bloomberg) -- Billionaire Ryan Cohen pocketed a $68.1 million profit from the sale of his stake in Bed Bath & Beyond Inc., scoring a 56% gain on an investment he held for roughly seven months.Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesStocks Slide as Short-Sellers Cash In on Fedspeak: Markets WrapMueller Memo Advising Barr on Trump Findings Is O
For investors looking to maximize their wealth by the time they retire, the following pair of beaten-down businesses that possess strong growth capabilities are a worthwhile place to start. Freelance marketplace operator Fiverr (NYSE: FVRR) was a pandemic-lockdown superstar. Although Fiverr's stock price is down 65% in 2022 and off 82% from its all-time high, the freelance shop is still growing, albeit at a slower rate as SMBs became more cautious due to rampant inflation and rising energy costs and interest rates.
Verizon (VZ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The past few weeks have been refreshing for Cathie Wood and fans of her style of growth stock investing. The CEO and co-founder of Ark Invest publishes the buys and sells of her firm's exchange-traded funds (ETFs) every market day, giving the public insight into her latest allocation strategies.
(Bloomberg) -- One big force at the center of the two-month equity rally is showing signs of fatigue. Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesStocks Slide as Short-Sellers Cash In on Fedspeak: Markets WrapMueller Memo Advising Barr on Trump Findings Is Ordered ReleasedIt’s the behavior of short sellers, whose frantic efforts to unwind bearish
CEO Mary Barra previously said the automaker plans to double its annual revenue by 2030 shifting its focus to electric and autonomous vehicles, connected services and new businesses.
Interactive Brokers Chief Strategist Steve Sosnick joins Yahoo Finance Live to discuss the wild week for Bed Bath & Beyond and investor Ryan Cohen exiting all of his shares of the company.
Oil stocks and chemicals dominate this list of today's fastest-growing stocks, all eyeing 111%-762% EPS gains this year.
Chasing best-known favorites may not be the best way to score on Meme stocks, analysts say. Meme stock ETFs can help.
(Bloomberg) -- Individual investors who flocked into Bed Bath & Beyond Inc. over the past week, trying to squeeze short sellers and make a killing backed in part by the belief a Ryan Cohen-led shakeup was well underway, are now sitting on $205 million in losses -- at the very least. Most Read from BloombergUS Mortgage Lenders Are Starting to Go BrokeXi and Putin to Attend G-20 Summit in Indonesia, Jokowi SaysApple Targets Sept. 7 for iPhone 14 Launch in Flurry of New DevicesStocks Slide as Short
Retail traders were quick to flock to the side of Chewy Inc (NYSE: CHWY) founder and GameStop Corp (NYSE: GME) chair Ryan Cohen when he purchased a stake in Bed Bath & Beyond Inc (NASDAQ: BBBY) in March. Less than six months later, Cohen has filed intent to sell his stake in the embattled retailer and accusations are flying. One institutional investor has suggested that Cohen used retail investors to pump the stock for his own benefit. What To Know: Luke Lloyd, wealth advisor and investment stra
Jake Freeman, the 20-year-old college student who reportedly banked $100 million trading Bed Bath and Beyond stock, purchased 4.69 million shares of the retailer Bed Bath & Beyond Inc (NASDAQ: BBBY) in July at roughly $5.20 per share along with his uncle, Dr. Scott Freeman. That netted their Freeman Capital Management family fund a 6.21% passive stake in the meme stock. “I wasn’t that aware it was a meme stock,” the University of Southern California student told Benzinga on Thursday. “I approach